Abstract
Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Current Gene Therapy
Title: Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Volume: 2 Issue: 1
Author(s): Antoni Ribas, Lisa H. Butterfield, John A. Glaspy and James S. Economou
Affiliation:
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Abstract: Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Export Options
About this article
Cite this article as:
Ribas Antoni, Butterfield H. Lisa, Glaspy A. John and Economou S. James, Cancer Immunotherapy Using Gene-Modified Dendritic Cells, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348129
DOI https://dx.doi.org/10.2174/1566523023348129 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Therapeutic Potential of Essential Oil-based Microemulsions: Reviewing State-of-the-art
Current Drug Delivery Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages
Current HIV Research Lessons Learned from HIV Vaccine Clinical Efficacy Trials
Current HIV Research Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Menstrual and Reproductive Outcomes Following Uterine Artery Fibroid Embolisation: A Literature Review
Current Women`s Health Reviews Trichomonas Vaginalis Infection Among Women Attending Laboratory Centers in Ilam, Iran
Infectious Disorders - Drug Targets The Role of Endocytic Pathways on Estrogen Receptor α Intracellular Trafficking and 17β-estradiol Signaling
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics
Current Pharmaceutical Design Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Stem Cell and Regenerative Medicine
Current Stem Cell Research & Therapy The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Cosmeceutical Aptitudes of Niacinamide: A Review
Recent Advances in Anti-Infective Drug Discovery Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design